acute coronary syndrome

     

Select            
Trial Studied trt Control trt patientstagsROB Trial resultMajor bleedingAll cause death

anti-anginal drugs  

ranolazine  
MERLIN TIMI 36, 2007      NCTranolazine placeboLow risk of bias suggesting-2%

anticoagulant  

apixaban  
APPRAISE-1 (10mg od), 2009      NCTapixabanplaceboLow risk of bias negative
APPRAISE-1 (2.5 mg bid), 2009      NCTapixabanplaceboLow risk of bias negative
APPRAISE 2, 2011      NCTapixabanplaceboLow risk of bias negative 153%8%
coumadin  
ASPECT-2 (coumadin+asp vs asp), 2002     coumadincontrol (on top of aspirin)suggesting135%
ASPECT-2 (coumadin vs aspirin), 2002   coumadinaspirinsuggesting3%
dabigatran  
REDEEM, 2009    NCTdabigatranplaceboLow risk of bias negative
otamixaban  
SEPIA-ACS1 TIMI 42, 2009    NCTotamixabanunfractionated heparinLow risk of bias suggesting
rivaroxaban  
ATLAS ACS 2 - TIMI 51 (2.5mg), 2011      NCTrivaroxaban 2.5mgplaceboLow risk of bias suggesting 243%-33%
ATLAS ACS-TIMI 46 (2.5mg), 2009      NCTrivaroxaban 2.5mgplaceboLow risk of bias negative276%
ATLAS ACS 2 - TIMI 51 (5mg), 2011      NCTrivaroxaban 5mgplacebosuggesting 333%-58%
ATLAS ACS-TIMI 46 (5mg), 2009      NCTrivaroxaban 5mgplaceboLow risk of bias negative 1664%
warfarin  
ATACS (pilot study) (warfarin vs control), 1990     warfarincontrol (on top of aspirin)negative-14%
ATACS, 1994   warfarincontrol (on top of aspirin)negative∞%
CARS, 1997     warfarincontrol (on top of aspirin)negative29%
OASIS Pilot (phase 1), 1998     warfarincontrol (on top of aspirin)negative∞%
OASIS Pilot (phase 2), 1998     warfarincontrol (on top of aspirin)negative102%
OASIS-2 Warfarin Substudy, 2001     warfarincontrol (on top of aspirin)negative 98%
APRICOT-2, 2002     warfarincontrol (on top of aspirin)negative3%
CHAMP, 2002     warfarincontrol (on top of aspirin)negative 75%
WARIS, 2002     warfarincontrol (on top of aspirin)suggesting 249%
LoWASA, 2004     warfarincontrol (on top of aspirin)negative 104%
Zibaeenezhad, 2004   warfarincontrol (on top of aspirin)negative150%
Williams, 1997     warfarinplacebo (on top of aspirin)Low risk of bias negative∞%
Huyhn, 2001     warfarinplacebo (on top of aspirin)Low risk of bias negative∞%
ATACS (pilot study) warfarin vs aspirin, 1990     warfarinaspirinnegative
ximelagatran  
ESTEEM, 2003   ximelagatranplaceboExploratory -

antiplatelets drug  

not classified  
Jones, 1987   dazoxibencontrolnegative
GRAND, 1987   GR3219Bcontrolnegative
Gent-AMI, 1968   misc.controlnegative
Johannessen, 1989     misc.controlnegative
French, 1993     flurbiprofenplaceboLow risk of bias suggesting-2%
CURRENT - OASIS 7 (ASA), 2010    NCTASA high doseASA low doseRisk of bias suggesting-1%-10%
aspirin  
ATACS-pilot, 1990   aspirincontrolnegative
Huddinge, 1988     aspirincontrolnegative
Frankfurt, 1976   aspirincontrolnegative
VA-pilot   aspirinplacebonegative
VA-main, 1983   aspirinplaceboLow risk of bias suggesting
RISC, 1990   aspirinplaceboLow risk of bias suggesting
ALDUSA-pilot   aspirinplacebonegative
Théroux, 1988   aspirinplaceboLow risk of bias suggesting
Canadian (Aspirin vs PBO), 1985   aspirinplaceboLow risk of bias -
Dutch-aspirin, 1990     aspirinplaceboLow risk of bias negative
ISIS-pilot, 1987     aspirinplaceboLow risk of bias negative-2%
ISIS-2, 1988   aspirinplaceboLow risk of bias suggesting34%
APRICOT, 1993   aspirinplaceboLow risk of bias suggesting
Canadian (Aspirin + sulfinpyrazone), 1985   aspirin + sulfinpyrazoneplaceboLow risk of bias negative
atopaxar  
J-LANCELOT, 2010   atopaxarplaceboExploratory -
LANCELOT ACS     atopaxarplaceboExploratory -
clopidogrel  
COMMIT, 2005      NCTclopidogrelplaceboLow risk of bias suggesting
CLARITY-TIMI 28, 2005   clopidogrelplaceboLow risk of bias -
CURE, 2001     clopidogrel + aspirinaspirinLow risk of bias suggesting 38%
CURRENT OASIS 7 (clopidogrel), 2010    NCTclopidogrel high-dose regimenclopidogrel standard-doseLow risk of bias negative 24%-4%
dipyridamol  
Prandoni, 1991   aspirin + dipyridamolplaceboLow risk of bias negative
elinogrel  
ERASE-MI, 2009     elinogrelplaceboLow risk of bias negative
prasugrel  
TRILOGY ACS (overall population), 2012        NCTprasugrelclopidogrelLow risk of bias negative21%-6%
TRITON-TIMI 38, 2007      NCTprasugrelclopidogrelLow risk of bias suggesting 31%-5%
sulfinpyrazone  
Dutch sulphinpyrazone, 1986   sulfinpyrazonecontrolnegative
Canadian (sulfinpyrazone alone), 1985   sulfinpyrazoneplaceboLow risk of bias -
Wilcox, 1980   sulfinpyrazoneplacebonegative
Louvain sulphinpyrazone, 1983   sulfinpyrazoneplaceboLow risk of bias negative
ticagrelor  
PLATO, 2009      NCTticagrelorclopidogrelLow risk of bias suggesting3%-22%
DISPERSE-2 (90mg), 2007       ticagrelorclopidogrelLow risk of bias negative-2%37%
ticlopidine  
STAI, 1990   ticlopidinecontrolsuggesting
Knudsen-A, 1985   ticlopidinecontrolnegative
Florida UA   ticlopidineplacebonegative
trapidil  
Modena   trapidilplacebosuggesting
triflusal  
Plaza, 1993   triflusalplaceboLow risk of bias suggesting
vorapaxar  
TRACER, 2011      NCTvorapaxarplacebo (on top standard therapy) Low risk of bias -

antithrombotics  

not classified  
Gurfinkel (LMWH+asp vs asp), 1995     LMWHplacebo (on top of aspirin)suggesting
CURRENT - OASIS 7 (ASA), 2010    NCTASA high doseASA low doseRisk of bias suggesting-1%-10%
Gurfinkel (LMWH+asp vs UFH+asp), 1995   LMWHUFH (on top of aspirin)suggesting -100%
apixaban  
APPRAISE-1 (10mg od), 2009      NCTapixabanplaceboLow risk of bias negative
APPRAISE-1 (2.5 mg bid), 2009      NCTapixabanplaceboLow risk of bias negative
APPRAISE 2, 2011      NCTapixabanplaceboLow risk of bias negative 153%8%
argatroban  
ARGAMI-2, 1998       Argatrobanheparin -
aspirin  
ATACS-pilot, 1990   aspirincontrolnegative
VA-pilot   aspirinplacebonegative
VA-main, 1983   aspirinplaceboLow risk of bias suggesting
RISC, 1990   aspirinplaceboLow risk of bias suggesting
ALDUSA-pilot   aspirinplacebonegative
Théroux, 1988   aspirinplaceboLow risk of bias suggesting
Canadian (Aspirin vs PBO), 1985   aspirinplaceboLow risk of bias -
Canadian (Aspirin + sulfinpyrazone), 1985   aspirin + sulfinpyrazoneplaceboLow risk of bias negative
atopaxar  
LANCELOT ACS     atopaxarplaceboExploratory -
J-LANCELOT, 2010   atopaxarplaceboExploratory -
bivalirudin  
ACUITY (biva alone vs hep+aGP2b3a), 2006      NCTbivalirudinheparin + GP2b3a inhibitorsLow risk of bias suggesting-23%19%
ACUITY (biva+aGP2b3a vs hep+aGP2b3a), 2006    NCTbivalirudin + GP2b3a inhibitorsheparin + GP2b3a inhibitorsLow risk of bias negative-6%13%
PROTECT-TIMI 30, 2006      NCTbivalirudineptifibatide + heparinExploratory -
HERO, 1997     bivalirudinheparinLow risk of bias suggesting
BAT (Bittl), 1995     bivalirudinheparinLow risk of bias suggesting
ACUITY (sub groups PCI, bivalirudin alone) importé, 2007         bivalirudinheparin + GP2b3a inhibitorssuggesting-48%19%
ACUITY (sub groups PCI, bivalirudin +aGP2b3a) importé, 2007     bivalirudin + GP2b3a inhibitorsheparin + GP2b3a inhibitorsnegative11%28%
clopidogrel  
CURE (PCI sub study), 2001     clopidogrelplaceboLow risk of bias -
CURE, 2001     clopidogrel + aspirinaspirinLow risk of bias suggesting 38%
CURRENT OASIS 7 (clopidogrel), 2010    NCTclopidogrel high-dose regimenclopidogrel standard-doseLow risk of bias negative 24%-4%
coumadin  
ASPECT-2 (coumadin+asp vs asp), 2002     coumadincontrol (on top of aspirin)suggesting135%
ASPECT-2 (coumadin vs aspirin), 2002   coumadinaspirinsuggesting3%
dalteparin  
FRISC (long term), 1996   dalteparinplacebo (on top of aspirin)Low risk of bias suggesting-15%
FRIC prolonged treatment phase (LWMH vs PBO), 1997     dalteparinplacebo (on top of aspirin)Low risk of bias negative61%
FRISC (short term), 1996   dalteparinplacebo (on top of aspirin)Low risk of bias -
FRIC (acute phase LMWH vs UFH), 1997     dalteparinUFH (on top of aspirin)Exploratory negative257%
dipyridamol  
Prandoni, 1991   aspirin + dipyridamolplaceboLow risk of bias negative
Efegatran  
Klootwijk, 1999     EfegatranheparinExploratory -
enoxaparin  
RESCUE    NCTenoxaparinunfractionated heparin -
EVET, 2005     enoxaparintinzaparinsuggesting-50%
ESSENCE, 1997     enoxaparinUFH (on top of aspirin)Low risk of bias suggesting -7%-3%
TIMI 11 B (short term), 1998   enoxaparinUFH (on top of aspirin)Low risk of bias suggesting 52%-17%
SYNERGY, 2005          NCTenoxaparinUFH (on top of aspirin)negative 19%4%
INTERACT, 2006       enoxaparinUFH (on top of aspirin)suggesting -60%-42%
TIMI 11 B (long term), 1998   enoxaparinUFH (on top of aspirin)Low risk of bias negative 90%-4%
fondaparinux  
PENTUA, 2004     fondaparinuxenoxaparin -
OASIS 5, 2006      NCTfondaparinuxenoxaparinLow risk of bias -
hirudin  
HIT-4, 1999     HirudinheparinLow risk of bias -
TIMI 9B, 1996     HirudinheparinRisk of bias -
GUSTO IIB, 1996     HirudinheparinRisk of bias -
OASIS pilot, 1997     HirudinheparinExploratory -
HELVETICA (Serruys), 1995     HirudinheparinLow risk of bias -
OASIS 2, 1999     HirudinheparinLow risk of bias -
OASIS, 1997   HirudinheparinRisk of bias -
inogatran  
TRIM, 1997     InogatranheparinLow risk of bias -
nadroparin  
FRAXIS (6days), 1998     nadroparinUFH (on top of aspirin)Low risk of bias negative6%
FRAXIS (14 days), 1998     nadroparinUFH (on top of aspirin)Low risk of bias negative26%
otamixaban  
SEPIA-ACS1 TIMI 42, 2009    NCTotamixabanunfractionated heparinLow risk of bias suggesting
prasugrel  
TRILOGY ACS (overall population), 2012        NCTprasugrelclopidogrelLow risk of bias negative21%-6%
TRITON-TIMI 38, 2007      NCTprasugrelclopidogrelLow risk of bias suggesting 31%-5%
rivaroxaban  
ATLAS ACS 2 - TIMI 51 (2.5mg), 2011      NCTrivaroxaban 2.5mgplaceboLow risk of bias suggesting 243%-33%
ATLAS ACS 2 - TIMI 51 (5mg), 2011      NCTrivaroxaban 5mgplacebosuggesting 333%-58%
sulfinpyrazone  
Canadian (sulfinpyrazone alone), 1985   sulfinpyrazoneplaceboLow risk of bias -
ticagrelor  
PLATO, 2009      NCTticagrelorclopidogrelLow risk of bias suggesting3%-22%
DISPERSE-2 (90mg), 2007       ticagrelorclopidogrelLow risk of bias negative-2%37%
ticlopidine  
STAI, 1990   ticlopidinecontrolsuggesting
Florida UA   ticlopidineplacebonegative
trapidil  
Modena   trapidilplacebosuggesting
triflusal  
TIM, 2000     triflusalaspirinLow risk of bias -
Plaza, 1993   triflusalplaceboLow risk of bias suggesting
UFH  
Holdright, 1994   UFHcontrol (on top of aspirin)negative-15%
RISC (heparin+aspirin vs ASP), 1990   UFHcontrol (on top of aspirin)negative
Theroux (heparin+ASP vs ASP), 1988   UFHcontrol (on top of aspirin)Low risk of bias suggesting
ATACS (Cohen), 1994   UFH, warfarincontrol (on top of aspirin)negative606%4%
Cohen (ATACS pilot) (heparin+aspirin vs asp), 1990     UFH, warfarincontrol (on top of aspirin)negative
Theroux (heparin vs PBO), 1988   UFHplaceboLow risk of bias suggesting0%-100%
RISC (heparin vs PBO), 1990   UFHplacebonegative
Theroux (heparin+aspirin vs PBO), 1988   UFH + aspirinplaceboLow risk of bias suggesting-100%
RISC (ASP+ heparin vs PBO), 1990   UFH + aspirinplacebosuggesting
Gurfinkel (UFH+aspririn vs aspirin), 1995     UFHplacebo (on top of aspirin)Low risk of bias negative421%
Cohen (ATACS pilot) (heparin vs asp), 1990     UFH, warfarinaspirinnegative
vorapaxar  
TRACER, 2011      NCTvorapaxarplacebo (on top standard therapy) Low risk of bias -
warfarin  
ATACS (pilot study) (warfarin vs control), 1990     warfarincontrol (on top of aspirin)negative-14%
ATACS, 1994   warfarincontrol (on top of aspirin)negative∞%
CARS, 1997     warfarincontrol (on top of aspirin)negative29%
OASIS Pilot (phase 1), 1998     warfarincontrol (on top of aspirin)negative∞%
OASIS Pilot (phase 2), 1998     warfarincontrol (on top of aspirin)negative102%
OASIS-2 Warfarin Substudy, 2001     warfarincontrol (on top of aspirin)negative 98%
APRICOT-2, 2002     warfarincontrol (on top of aspirin)negative3%
CHAMP, 2002     warfarincontrol (on top of aspirin)negative 75%
WARIS, 2002     warfarincontrol (on top of aspirin)suggesting 249%
LoWASA, 2004     warfarincontrol (on top of aspirin)negative 104%
Zibaeenezhad, 2004   warfarincontrol (on top of aspirin)negative150%
Williams, 1997     warfarinplacebo (on top of aspirin)Low risk of bias negative∞%
Huyhn, 2001     warfarinplacebo (on top of aspirin)Low risk of bias negative∞%
ATACS (pilot study) warfarin vs aspirin, 1990     warfarinaspirinnegative
ximelagatran  
ESTEEM, 2003   ximelagatranplaceboExploratory -

calcium channel blockers  

diltiazem  
Göbel (Dutch study), 1995   diltiazemplaceboLow risk of bias -
DRS, 1986   diltiazemplaceboLow risk of bias -
nifedipine  
HINT (nifedipine vs metoprolol), 1988   nifedipinemetoprolol -

cholesterol lowering intervention  

not classified  
JAPAN ACS, 2009      NCTpitavastatinatorvastatinacute coronary syndrome early initiation Exploratory -
atorvastatin  
MIRACL, 2001     atorvastatinplaceboacute coronary syndrome early initiation Low risk of bias suggesting-5%
Colivicchi, 2002     atorvastatinusual careacute coronary syndrome early initiation Exploratory negative-23%
ESTABLISH, 2004     atorvastatinusual careacute coronary syndrome early initiation Exploratory negative-100%
PROVE IT - TIMI 22, 2004     atorvastatinpravastatinacute coronary syndrome early initiation Low risk of bias suggesting-28%
ezetimibe  
IMPROVE-IT, 2014      NCTezetimibeplacebo (on top statins) early initiation Low risk of bias conclusive-1%
fluvastatin  
LIPS (sub groups), 2002     fluvastatinplaceboacute coronary syndrome early initiation Low risk of bias negative-27%
FLORIDA, 2002     fluvastatinplaceboacute coronary syndrome early initiation Low risk of bias negative-34%
pravastatin  
LAMIL, 1997   pravastatinplaceboacute coronary syndrome early initiation Low risk of bias negative
RECIFE, 1999     pravastatinplaceboacute coronary syndrome early initiation Low risk of bias negative
PAIS, 2001   pravastatinplaceboacute coronary syndrome early initiation Low risk of bias negative
PACT, 2004     pravastatinplaceboacute coronary syndrome early initiation Low risk of bias suggesting-31%
L-CAD, 2000     pravastatinusual careacute coronary syndrome early initiation Exploratory suggesting-20%
PTT, 2002   pravastatinusual careacute coronary syndrome early initiation Exploratory suggesting
simvastatin  
A to Z, 2004     simvastatinplaceboacute coronary syndrome early initiation negative-10%

direct factor Xa inhibitors  

apixaban  
APPRAISE-1 (10mg od), 2009      NCTapixabanplaceboLow risk of bias negative
APPRAISE-1 (2.5 mg bid), 2009      NCTapixabanplaceboLow risk of bias negative
APPRAISE 2, 2011      NCTapixabanplaceboLow risk of bias negative 153%8%
dabigatran  
REDEEM, 2009    NCTdabigatranplaceboLow risk of bias negative
otamixaban  
SEPIA-ACS1 TIMI 42, 2009    NCTotamixabanunfractionated heparinLow risk of bias suggesting
rivaroxaban  
ATLAS ACS 2 - TIMI 51 (2.5mg), 2011      NCTrivaroxaban 2.5mgplaceboLow risk of bias suggesting 243%-33%
ATLAS ACS-TIMI 46 (2.5mg), 2009      NCTrivaroxaban 2.5mgplaceboLow risk of bias negative276%
ATLAS ACS 2 - TIMI 51 (5mg), 2011      NCTrivaroxaban 5mgplacebosuggesting 333%-58%
ATLAS ACS-TIMI 46 (5mg), 2009      NCTrivaroxaban 5mgplaceboLow risk of bias negative 1664%
ximelagatran  
ESTEEM, 2003   ximelagatranplaceboExploratory -

direct oral anticoagulant (DAO)  

apixaban  
APPRAISE-1 (10mg od), 2009      NCTapixabanplaceboLow risk of bias negative
APPRAISE-1 (2.5 mg bid), 2009      NCTapixabanplaceboLow risk of bias negative
APPRAISE 2, 2011      NCTapixabanplaceboLow risk of bias negative 153%8%
dabigatran  
REDEEM, 2009    NCTdabigatranplaceboLow risk of bias negative
otamixaban  
SEPIA-ACS1 TIMI 42, 2009    NCTotamixabanunfractionated heparinLow risk of bias suggesting
rivaroxaban  
ATLAS ACS 2 - TIMI 51 (2.5mg), 2011      NCTrivaroxaban 2.5mgplaceboLow risk of bias suggesting 243%-33%
ATLAS ACS-TIMI 46 (2.5mg), 2009      NCTrivaroxaban 2.5mgplaceboLow risk of bias negative276%
ATLAS ACS 2 - TIMI 51 (5mg), 2011      NCTrivaroxaban 5mgplacebosuggesting 333%-58%
ATLAS ACS-TIMI 46 (5mg), 2009      NCTrivaroxaban 5mgplaceboLow risk of bias negative 1664%
ximelagatran  
ESTEEM, 2003   ximelagatranplaceboExploratory -

fibrinolysis  

not classified  
TAUSA, 1994   intracoronary urokinaseplaceboLow risk of bias negative
anistreplase  
UNASEM, 1992   anistreplaseplaceboLow risk of bias -
t-pa  
Nicklas, 1989   t-PAplaceboLow risk of bias negative
Gold, 1987   t-PAplaceboExploratory -
Williams, 1990   t-PAplaceboLow risk of bias negative
Freeman, 1992   t-PAplaceboLow risk of bias negative0%
van der Brand, 1991     t-PAplaceboLow risk of bias negative
charbonnier, 1992   t-PAplaceboLow risk of bias -
Ardissino, 1990     t-PAplaceboLow risk of bias negative
TIMI 3B, 1995     t-PAplaceboLow risk of bias -
Topol, 1988   t-PAplaceboExploratory negative
TIMI 3A, 1993   t-PAplaceboLow risk of bias -

heparin (UFH or LMWH)  

not classified  
Gurfinkel (LMWH+asp vs asp), 1995     LMWHplacebo (on top of aspirin)suggesting
Gurfinkel (LMWH+asp vs UFH+asp), 1995   LMWHUFH (on top of aspirin)suggesting -100%
dalteparin  
FRISC (long term), 1996   dalteparinplacebo (on top of aspirin)Low risk of bias suggesting-15%
FRIC prolonged treatment phase (LWMH vs PBO), 1997     dalteparinplacebo (on top of aspirin)Low risk of bias negative61%
FRISC (short term), 1996   dalteparinplacebo (on top of aspirin)Low risk of bias -
FRIC (acute phase LMWH vs UFH), 1997     dalteparinUFH (on top of aspirin)Exploratory negative257%
enoxaparin  
RESCUE    NCTenoxaparinunfractionated heparin -
EVET, 2005     enoxaparintinzaparinsuggesting-50%
ESSENCE, 1997     enoxaparinUFH (on top of aspirin)Low risk of bias suggesting -7%-3%
TIMI 11 B (short term), 1998   enoxaparinUFH (on top of aspirin)Low risk of bias suggesting 52%-17%
SYNERGY, 2005          NCTenoxaparinUFH (on top of aspirin)negative 19%4%
INTERACT, 2006       enoxaparinUFH (on top of aspirin)suggesting -60%-42%
TIMI 11 B (long term), 1998   enoxaparinUFH (on top of aspirin)Low risk of bias negative 90%-4%
nadroparin  
FRAXIS (6days), 1998     nadroparinUFH (on top of aspirin)Low risk of bias negative6%
FRAXIS (14 days), 1998     nadroparinUFH (on top of aspirin)Low risk of bias negative26%
UFH  
Holdright, 1994   UFHcontrol (on top of aspirin)negative-15%
RISC (heparin+aspirin vs ASP), 1990   UFHcontrol (on top of aspirin)negative
Theroux (heparin+ASP vs ASP), 1988   UFHcontrol (on top of aspirin)Low risk of bias suggesting
ATACS (Cohen), 1994   UFH, warfarincontrol (on top of aspirin)negative606%4%
Cohen (ATACS pilot) (heparin+aspirin vs asp), 1990     UFH, warfarincontrol (on top of aspirin)negative
Theroux (heparin vs PBO), 1988   UFHplaceboLow risk of bias suggesting0%-100%
RISC (heparin vs PBO), 1990   UFHplacebonegative
Theroux (heparin+aspirin vs PBO), 1988   UFH + aspirinplaceboLow risk of bias suggesting-100%
RISC (ASP+ heparin vs PBO), 1990   UFH + aspirinplacebosuggesting
Gurfinkel (UFH+aspririn vs aspirin), 1995     UFHplacebo (on top of aspirin)Low risk of bias negative421%
Cohen (ATACS pilot) (heparin vs asp), 1990     UFH, warfarinaspirinnegative

myocardial revascularization  

not classified  
TAUSA, 1994   intracoronary urokinaseplaceboLow risk of bias negative
FRISC 2, 1999         routine invasive strategyconcervative strategysuggesting 113%-32%
TACTICS-TIMI 18, 2001     routine invasive strategyconcervative strategysuggesting -6%
VINO, 2002     routine invasive strategyconcervative strategysuggesting-77%
RITA 3, 2002       routine invasive strategyconcervative strategysuggesting -15%
ICTUS, 2007       routine invasive strategyconcervative strategysuggesting -1%
TRUCS, 2000     routine invasive strategyconcervative strategynegative-68%
NQWMI (Eisenberg), 2005     routine invasive strategyconcervative strategyExploratory negative10%
TACTICS-TIMI 18 elderly (sub group), 2001     routine invasive strategyconcervative strategysuggesting -12%
TIMI 3B (PTCA), 1994   routine invasive strategy - noncomptemporaryconcervative strategysuggesting-6%
VANQWISH, 1998     routine invasive strategy - noncomptemporaryconcervative strategysuggesting34%
MATE, 1998     routine invasive strategy - noncomptemporaryconcervative strategynegative8%
TIMACS, 2009    NCTearly invasive managementdelayed invasive strategyRisk of bias suggesting-11%-19%
ABOARD, 2009    NCTimmediate invasive managementdelayed invasive strategyExploratory negative-41%153%
OPTIMA, 2009   immediate invasive managementdelayed invasive strategyRisk of bias suggesting -53%
ISAR-COOL, 2003     early interventionearly strategysuggesting 31%∞%
VA cooperative, 1987   surgerymedical treatmentRisk of bias -
anistreplase  
UNASEM, 1992   anistreplaseplaceboLow risk of bias -
t-pa  
Nicklas, 1989   t-PAplaceboLow risk of bias negative
Gold, 1987   t-PAplaceboExploratory -
Williams, 1990   t-PAplaceboLow risk of bias negative
Freeman, 1992   t-PAplaceboLow risk of bias negative0%
van der Brand, 1991     t-PAplaceboLow risk of bias negative
charbonnier, 1992   t-PAplaceboLow risk of bias -
Ardissino, 1990     t-PAplaceboLow risk of bias negative
TIMI 3B, 1995     t-PAplaceboLow risk of bias -
Topol, 1988   t-PAplaceboExploratory negative
TIMI 3A, 1993   t-PAplaceboLow risk of bias -

New P2Y12 Inhibitors  

cangrelor  
CHAMPION-PCI, 2009      NCTcangrelor up frontclopidogrel up frontLow risk of bias negative59%
CHAMPION-PLATFORM, 2009    NCTcangrelor up frontdelayed clopidogrelLow risk of bias negative
elinogrel  
ERASE-MI, 2009     elinogrelplaceboLow risk of bias negative
prasugrel  
JUMBO-TIMI 26, 2005   prasugrelclopidogrelLow risk of bias negative
TRITON-TIMI 38, 2007      NCTprasugrelclopidogrelLow risk of bias suggesting 31%-5%
ticagrelor  
PLATO, 2009      NCTticagrelorclopidogrelLow risk of bias suggesting3%-22%
DISPERSE-2 (90mg), 2007       ticagrelorclopidogrelLow risk of bias negative-2%37%

nitrates  

nitroglycerin  
Doucet, 2000     placeboLow risk of bias -
Karlberg, 1998     placeboLow risk of bias -

oxygen therapy  

not classified  
Dekleva, 2004       errorcontrolnegative-100%
Sharifi, 2004     hyperbaric oxygencontrolsuggesting-100%
Swift, 1992   hyperbaric oxygencontrol -
Thurston, 1973     hyperbaric oxygencontrolsuggesting-43%
Hot MI, 1997       hyperbaric oxygencontrolnegative-30%
HOT MI pilot, 1997     Hyperbaric oxygencontrol -
Rawles, 1976   oxygen therapycontrolnegative
Ukholkina, 2005   oxygen therapycontrolnegative
Wilson, 1997   oxygen therapycontrolnegative
AMIHOT II , 2000      NCTsupersaturated oxygencontrol -
AMIHOT, 2007       supersaturated oxygencontrol -
Kerr, 1975   EntonoxplaceboLow risk of bias -